Please ensure Javascript is enabled for purposes of website accessibility

Why Tyme Technologies Stock Is Crushing It Today

By Keith Speights - Feb 3, 2021 at 12:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The U.S. Patent and Trademark Office is on Tyme's side.

What happened

Shares of Tyme Technologies (TYME -1.46%) were skyrocketing 84.9% higher as of 12:09 p.m. EST on Wednesday after rising as much as 174% earlier in the day. This huge gain came after the company announced that the U.S. Patent and Trademark Office (USPTO) had granted another patent related to a COVID-19 treatment using Tyme's metabolomic technology platform.

So what

It's not unusual for clinical-stage biotech stocks like Tyme to go into orbit after good news. But just how good was Tyme's news? The answer lies in how its metabolomic technology works.

Patent application with "approved" stamp with a pen on top of the document and a cup of coffee next to it

Image source: Getty Images.

Most immune therapies and vaccines targeting COVID-19 focus on the external virus coating, especially the spike proteins on the coronavirus surface. That's a good approach, but it's possible that genetic mutations to the virus could make these therapies and vaccines less effective.

Tyme's experimental TYME-19 therapy shouldn't be affected by genetic mutations to the coronavirus coat. TYME-19 could limit viral replication by inhibiting the ability of the coronavirus to produce viral proteins and fatty acids. 

Obtaining the U.S. patent for this approach isn't a big deal if TYME-19 proves to be ineffective at preventing COVID-19. However, if Tyme's pipeline candidate is successful, the patent could protect the biotech's intellectual property rights and enable it to make a lot of money in the future.

Now what

Tyme plans to advance TYME-19 into clinical testing soon and release results later this year. It also continues to enroll participants in a pivotal study of SM-88 as a potential third-line treatment for pancreatic cancer. Another potential catalyst could be on the way this year in the form of expected results from a phase 2 study conducted by the Joseph Ahmed Foundation evaluating SM-88 as a maintenance monotherapy in previously treated Ewing's sarcoma (a rare type of bone cancer) and as a salvage monotherapy in clinically advanced sarcomas.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Tyme Technologies, Inc. Stock Quote
Tyme Technologies, Inc.
TYME
$0.27 (-1.46%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/23/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.